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Abstract
AIM: To evaluate variation of the concentration of 
thiopurine metabolites after 5-aminosalicylate (5-ASA) 
interruption and the role of genetic polymorphisms of 
N-acetyl transferase (NAT) 1 and 2. 
METHODS: Concentrations of thioguanine nucleotides 
(TGN) and methymercaptopurine nucleotides (MMPN), 
metabolites of thiopurines, were measured by high 
performance liquid chromatography in 12 young 
patients (3 females and 9 males, median age 16 
years) with inflammatory bowel disease (6 Crohn’s 
disease and 6 ulcerative colitis) treated with thiopurines 
(7 mercaptopurine and 5 azathioprine) and 5-ASA. 
Blood samples were collected one month before and 
one month after the interruption of 5-ASA. DNA was 
extracted and genotyping of NAT1 , NAT2 , inosine 
triphosphate pyrophosphatase (ITPA ) and thiopurine 
methyl transferase (TPMT ) genes was performed using 
PCR assays. 
RESULTS: Median TGN concentration before 5-ASA 
interruption was 270 pmol/8 x 108 erythrocytes (range: 
145-750); after the interruption of the aminosalicylate, 
a 35% reduction in TGN mean concentrations (absolute 
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mean reduction 109 pmol/8 × 108 erythrocytes) was 
observed (median 221 pmol/8 × 108 erythrocytes, 
range: 96-427, P  value linear mixed effects model 
0.0011). Demographic and clinical covariates were 
not related to thiopurine metabolites concentrations. 
All patients were wild-type for the most relevant ITPA 
and TPMT variants. For NAT1 genotyping, 7 subjects 
presented an allele combination corresponding to 
fast enzymatic activity and 5 to slow activity. NAT1 
genotypes corresponding to fast enzymatic activity were 
associated with reduced TGN concentration (P  value 
linear mixed effects model 0.033), putatively because of 
increased 5-ASA inactivation and consequent reduced 
inhibition of thiopurine metabolism. The effect of NAT1 
status on TGN seems to be persistent even after one 
month since the interruption of the aminosalicylate. 
No effect of NAT1 genotypes was shown on MMPN 
concentrations. NAT2 genotyping revealed that 6 
patients presented a genotype corresponding to 
fast enzymatic activity and 6 to slow activity; NAT2 
genotypes were not related to thiopurine metabolites 
concentration in this study. 
CONCLUSION: NAT1 genotype affects TGN levels in 
patients treated with thiopurines and aminosalicylates 
and could therefore influence the toxicity and efficacy 
of these drugs; however the number of patients 
evaluated is limited and this has to be considered a 
pilot study. 
Key words: Thiopurines; Aminosalicylates; Inflammatory 
bowel diseases; N-acetyl transferase; Pharmacogenomics
© The Author(s) 2015. Published by Baishideng Publishing 
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Core tip: During treatment of inflammatory bowel 
disease with thiopurines and aminosalicylates, inter-
ruption of the aminosalicylate results in a significant 
decrease in thiopurines’ thioguanine nucleotides (TGN) 
active metabolites. Genetic polymorphisms in genes 
involved in aminosalicylates biotransformation (NAT1 
genotype) affects TGN levels in patients treated with 
thiopurines and aminosalicylates and could therefore 
influence the toxicity and efficacy of these drugs. 
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INTRODUCTION
Thiopurines and aminosalicylates are the two most 
widely used drugs in inflammatory bowel disease (IBD) 
and are often used in combination. The thiopurines 
6-mercaptopurine (6MP) and its prodrug azathioprine 
(AZA) are effective in inducing and maintaining 
remission and are considered steroid sparing agents. 
6MP is metabolized by a multistep enzymatic pathway, 
initiated by hypoxanthine phosphoribosyl transferase 
that leads to formation of thioguanine nucleotides 
(TGNs). These active metabolites act as purine 
antagonist and inhibit DNA, RNA and protein synthesis, 
inducing cytotoxicity and immunosuppression. Blood 
levels of thiopurine metabolites have been correlated 
with the efficacy and toxicity of these drugs in patients 
with IBD: TGN levels higher than 235 pmol/8 x 108 
red blood cells are considered therapeutic, and methyl 
mercaptopurine nucleotides (MMPNs) levels above 5700 
pmol/8 x 108 red blood cells have been associated with 
hepatotoxicity[1-3]. 
The aminosalicylate 5-aminosalicylic acid (mesalazine, 
5-ASA) is used in the induction and maintenance of 
remission in ulcerative colitis[4,5]. In Crohn’s disease, the 
use of aminosalicylates is controversial, however studies 
suggest that they could have a role in the postoperative 
maintenance of remission also in this IBD[6]. In addition, 
a chemopreventive role of 5-ASA in IBD against colon 
cancer has been suggested[7].
An increase in mean TGN blood levels has been 
reported in patients on 6MP or AZA co-treated with 
5-ASA[2,8-12]. Even more important, a higher rate of 
myelotoxicity was observed in patients treated with 
this combination in comparison with those treated with 
the thiopurine alone[2,9,13]. 
6MP is inactivated by the enzyme thiopurine 
methyltransferase (TPMT, EC 2.1.1.67) that catalyzes 
its S-methylation to 6-methylmercaptopurine and, at 
least in part by inosine triphosphate pyrophosphatase 
(ITPA, EC 3.6.1.19). In vitro studies have shown that 
aminosalicylates and their metabolites can inhibit the 
activity of TPMT[14,15], however, this observation has not 
been confirmed in vivo[2,8,9].
The enzymes N-acetyltransferases (NAT1 and 
NAT2, EC 2.3.1.5) are responsible for the N-acetylation 
of a number of xenobiotics and drugs including the 
aminosalicylates. Even the activity of NAT1 and NAT2 
is genetically determined and subjects are classified as 
rapid, intermediate or slow acetylators. Although NAT1 
and NAT2 polymorphisms have been associated with 
the incidence of some diseases, no significant effect 
has been reported for IBD[16]. 5-ASA is inactivated 
primarily by the NAT1 isoform in the colonic mucosa, 
and the drug and its metabolites are excreted in 
the urine[17-19]. The inheritance of a slow acetylator 
genotype for NAT1 could therefore lead to a reduced 
inactivation of 5-ASA, and hence to higher blood levels 
of the drug.
The aim of this study was to measure variation 
of the concentration of thiopurine metabolites after 
5-ASA interruption and to evaluate the role of 
genetic polymorphisms of NAT1 and NAT2 on this 
phenomenon.
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MATERIALS AND METHODS
Patients and inclusion criteria
Twelve patients with IBD were enrolled by the 
Gastroenterology Unit of the Pediatric Hospital “Burlo 
Garofolo” in Trieste, and by the Research Children’s 
Hospital “Meyer”, Florence, Italy. These patients have 
been retrospectively selected considering the following 
criteria: previous diagnosis of IBD and treatment with 
AZA or 6MP plus 5-ASA for at least three months. 5-ASA 
therapy was interrupted, and a minimum of two blood 
samples for thiopurine metabolites measurement were 
taken one month before and one month after 5-ASA 
interruption. The study was approved by the local 
ethical committees and appropriate informed consent 
was obtained from all patients or their parents or 
guardians.
Measurement of azathioprine metabolites
Azathioprine metabolites (TGN and MMPN) were 
measured in patients’ erythrocytes using an HPLC 
assay by Dervieux and Boulieu[20] within few weeks 
from the sample collection. The ratio between TGN and 
the dose of azathioprine was calculated to account for 
the respective dose each patient was taking on the day 
that the metabolite testing was performed. 
Genotypes
Genomic DNA was extracted from peripheral blood 
samples using a commercial kit (SIGMA, Milan, Italy), 
in order to characterize genetic polymorphisms in the 
candidate genes NAT1, NAT2, TPMT and ITPA. The 
considered genotypes and method of analysis are 
described in Table 1. 
NAT acetylator status determination
NAT acetylator status (i.e., rapid or slow) was assessed 
from the genotyping results. In particular, for NAT1, 
patients with an A nucleotide at both 1088 and 1095 
nucleotides, corresponding to NAT1*10 allele, were 
considered as fast NAT1 acetylators while all other 
genotype combinations were considered as slow NAT1 
acetylators[21,22]. For NAT2, patients homozygous for 
the wild-type allele at either the 282 or 341 position or 
patients heterozygous for the variant allele at just one 
of these two positions were considered as fast NAT2 
acetylators, all other genotypes combinations were 
considered as slow NAT2 acetylators[23,24].
Statistical analysis
Statistical analysis was performed using the software R 
(version 3.0.1).
The primary intended outcome of this study was to 
evaluate variations of the concentration of thiopurine 
metabolites after 5-ASA interruption and the role of 
genetic polymorphisms of NAT 1 and 2.
Power analyses on preliminary data available 
indicate that given the difference in means and the 
distribution’s standard deviation, the minimum sample 
size to identify a statistically significant (P = 0.05, 
power 80%) result is 9 for the paired test comparing 
azathioprine metabolites during aminosalicylate 
treatment and after the suspension. For the analysis 
comparing thiopurine metabolites concentration in 
NAT1 fast acetylators compared to slow acetylators, 
the minimum number of patients to detect a statis-
tically significant (P = 0.05, power 80%) result is 5 for 
each NAT1 activity status.
The association between pharmacological pheno-
types of interest (i.e., TGN metabolites concentrations, 
MMPN metabolites concentrations) and the considered 
demographic variables, IBD type, co-treatment with 
aminosalicylate or genotypes in a univariate analysis, 
was evaluated by considering for each phenotype and 
patient the individual observations and evaluating 
the effect of each covariate by calculating the P 
value from a linear mixed effects model built using 
the phenotype as the dependent variable, each 
covariate as the fixed effect and the patients as the 
random effect in the model. Multivariate analysis 
was done to test the independence of the effects of 
the covariates significant in the univariate analysis 
on the phenotypes considered by using linear mixed 
effects models with the phenotype of interest as the 
independent variables and the covariates selected in 
the univariate analysis as the dependent variables. 
For all parametric analyses (i.e., linear mixed effects 
models used in the univariate analysis and the 
multivariate analysis), normality of the phenotype was 
tested by the Shapiro test and log10 transformation 
was applied if needed, in order to achieve normality 
of the distribution.
RESULTS
Patients enrolled and samples collected
The present study recruited 12 young patients (3 
females and 9 males, median age 16 years) with IBD 
(6 Crohn’s disease and 6 ulcerative colitis). Seven 
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Table 1  Genotypes and methods of analysis considered in 
this study
Gene Polymorphism Method References
NAT1 T1088A Sequencing With primer forward: 5’-TGCCC
AAACATGGTGATAGATTT-3’
With primer reverse: 5’-CCATAA
AACTTTTCTAGGAATTCAACA
AT-3’
NAT1 C1095A Sequencing As above
NAT2 C282T PCR-RFLP [23,24]
NAT2 T341C PCR-RFLP [23,24]
TPMT G238C PCR-ASO [27]
TPMT G460A PCR-RFLP [27]
TPMT A719G PCR-RFLP [27]
ITPA C94A TaqMan TaqMan SNP genotyping assay 
from
Applied biosystems 
(C_27465000_10)
Stocco G et al . Azathioprine metabolites and aminosalicylates treatment for IBD
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effects model 0.14). There was a significant correlation 
between TGN and MMPN concentrations (coefficient 
0.3, 95%CI: 0.15-0.45, linear mixed effect P value 
0.0007) while the dose of thiopurine did not correlate 
with TGN and MMPN concentrations in these patients. 
The dose of thiopurine did not change before and after 
the interruption of the aminosalicylate (median value 
of azathioprine dose and range 2.08 mg/kg, range: 
1.04-2.6).
Demographic and clinical covariates and azathioprine 
dose and metabolites
For the demographic (gender and age) and clinical (type 
of IBD and treatment duration) covariates considered, 
none showed a fully significant effect on the median 
TGN or MMPN concentrations in a univariate analysis 
(Table 2). 
Genotyping
All polymorphisms considered were respecting 
Hardy-Weinberg equilibrium and their distribution is 
comparable to what has been reported in the literature 
for patients of Caucasian ethnicity. All patients were 
wild-type for the most relevant ITPA and TPMT 
variants. For NAT1 genotyping, 7 presented an allele 
combination corresponding to fast enzymatic activity 
and 5 to slow activity. NAT2 genotyping revealed that 
6 patients presented a genotype corresponding to fast 
enzymatic activity and 6 to slow activity.
Genotypes and thiopurine metabolites
NAT1 genotypes corresponding to fast enzymatic 
activity was associated with reduced TGN concentration 
[coefficient = -0.159, 95%CI: -0.28-(-0.04), P value 
linear mixed effects model 0.033]: mean values 
were 269.3 and 400.8 respectively in patients with 
fast and slow NAT1 status before 5-ASA interruption, 
and 181.9 and 261.6 after 5-ASA interruption. 
Unexpectedly, the effect of NAT1 status on TGN seems 
to be persistent even one month since the interruption 
patients were treated with 6MP (median dosage 1.0 
mg/kg, range: 0.5-1.0, equivalent to a median AZA 
dose of 2.08 mg/kg, range: 1.04-2.08) and 5 with 
AZA (median dosage 2.2 mg/kg, range: 1.6-2.6). All 
patients were co-treated with 5-ASA for at least three 
months at standard doses (50 mg/kg). A total of 36 
samples of peripheral blood were collected to measure 
azathioprine metabolites; on average, 3 samples for 
patient were collected (range: 2-4). For 8 patients it 
was not possible to collect two samples before 5-ASA 
interruption and 2 samples after 5-ASA interruption, 
because of clinical reasons: therefore 12 samples 
(5 before and 7 after) were missing; however each 
patient had at least one sample before and one after 
5-ASA interruption. Among these, 19 were obtained 
during treatment with the thiopurines and 5-ASA, 
before 5-ASA interruption, and 17 after interruption 
of 5-ASA and therefore during treatment with the 
thiopurine alone. The reason for 5-ASA interruption 
was clinical, mostly simplification of therapy to increase 
compliance, which is particularly useful in pediatric 
patients. Samples were taken from the same patient 
with an interval of at least one month.
Measurement of azathioprine metabolites
Median TGN concentrations before 5-ASA interruption 
was 270 pmol/8 x 108 erythrocytes (range: 145-750); 
after the interruption of the aminosalicylate, a 35% 
reduction (mean absolute value 109 pmol/8 x 108 
erythrocytes) in TGN mean concentrations was 
observed [median 221 pmol/8 × 108 erythrocytes, 
range: 96-427, coefficient = -0.18, 95%CI: 
-0.27-(-0.09), P value linear mixed effects model 
0.0011]. MMPN concentration were not affected 
significantly by interruption of the aminosalicylate, with 
a median value of 1059 pmol/8 x 108 erythrocytes, 
range 246-17943 before the interruption in comparison 
to a median of 1071 pmol/8 × 108 erythrocytes, 
range 209-4531 after the interruption (coefficient = 
-0.13, 95%CI: -0.29-(-0.03), P value linear mixed 
Table 2  Demographic, clinical and pharmacological data for the 12 patients enrolled
Patient Age at 
enrollment (yr)
Disease Thiopurine 
dose (mg/kg 
per day)
5-ASA dose 
(mg/d)
TGN concentration1 % TGN change NAT1 status
Before After
1   7.7 CD AZA 2.6 50 244 218 -11% Rapid
2 17.3 CD AZA 2.2 50  2102 176 -16% Rapid
3 17.8 CD AZA 1.6 50  2762 101 -64% Rapid
4 14.7 CD 6MP 1.0 50  2882  1422 -51% Rapid
5 10.4 UC 6MP 0.6 50  3102  2062 -34% Rapid
6 14.5 UC 6MP 0.5 50  3302  1882 -43% Rapid
7 11.9 UC 6MP 1.0 50 228 243 +7% Rapid
8 17.4 CD AZA 2.2 50  2172 221 +2% Slow
9   6.3 UC AZA 2.3 50 375 140 -63% Slow
10 17.5 UC 6MP 1.0 50  6472  4012 -38% Slow
11 17.3 UC 6MP 1.0 50 264 278 +5% Slow
12 16.6 CD 6MP 0.5 50 501  2682 -47% Slow
1Pmol/8 × 108 erythrocytes; 2This value is the average of two measurements. 5-ASA: 5-aminosalicylate; TGN: 6-thioguanine nucleotides; NAT1: 
N-acetyltransferase 1; CD: Crohn’s disease; UC: Ulcerative colitis; 6MP: 6-mercaptopurine; AZA: Azathioprine.
Stocco G et al . Azathioprine metabolites and aminosalicylates treatment for IBD
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of the aminosalicylate (Figure 1). No effect of NAT1 
genotypes was shown on MMPN concentrations. NAT2 
genotypes were not related to thiopurine metabolites' 
concentration in this study.
DISCUSSION
The clinical use of thiopurines in IBDs has increased 
substantially in recent years; these drugs have 
indeed a steroid sparing effect[25] and their use in 
combination with infliximab has been also advocated[26]. 
Coprescription of 5-ASA is also common, and up to 
60% of patients on thiopurines are also treated with 
an aminosalicylate. 
Thiopurines are generally well tolerated, however, 
15%-20% of patients develop side effects such as 
leukopenia, hepatitis and pancreatitis[27-30]. Two key 
enzymes, TPMT and ITPA, are important for 6MP 
metabolism: TPMT catalyzes the S-methylation to 
6MP and genetic polymorphisms in the TPMT gene 
are associated with a reduced enzymatic activity 
and an increased production of the active TGNs; 
indeed, patients with the homozygous mutation are 
at high risk of severe and sometimes fatal immuno-
suppression. For this reason TPMT genotyping or 
phenotyping is recommended prior to the initiation 
of therapy. Another important enzyme in thiopurines' 
metabolism is ITPA; a polymorphism in this gene 
leads to accumulation of the metabolite 6-thioinosine 
triphosphate and has been associated with an 
increased risk of toxicity, in particular pancreatitis, flu 
like symptoms, rash and gastrointestinal toxicity[31]; 
this observation was however not confirmed by other 
studies[32,33]. All patients included in our study had a 
normal TPMT genotype and were wild-type for the 
most common mutation of ITPA, hence excluding bias 
due to the influence of these genotypes. 
In IBD patients treated with thiopurines an additional 
risk results from the co-administration of other drugs, 
such as the aminosalicylates. In the present study 
we confirm previous observations[2,8,9,11,13,34] of a 
significant decrease in TGN levels after discontinuation 
of 5-ASA. Furthermore, a dose dependent effect was 
previously reported for two different 5-ASA doses 
on thiopurine metabolites levels[35]. In our study all 
patients were treated with a dose of 5-ASA of 50 mg/
kg, equivalent to the higher dose reported by de Graaf 
et al[35]. Consistently with this study, after interruption 
of 5-ASA we observed an effect on TGN and not on 
MMPN concentration. This may be due to the different 
populations considered: TPMT activity indeed is 
significantly higher in wild-type children (0.08-17 years) 
than in wild-type adults (aged 18-68 years)[36]. 
The mechanism of this interaction is however 
still unclear. It has been demonstrated that the 
aminosalicylates inhibit the activity of recombinant 
TPMT in vitro[37,38], with IC50 values of 78 and 1240 
µmol/L for sulfasalazine and 5-ASA respectively. In 
in vivo studies, an increase in TGN levels and in the 
prevalence of leukopenia was observed in patients 
treated with azathioprine and 5-ASA; however, short 
term investigations in patients with IBD[8-11] did not 
demonstrate any significant change in TPMT activity. 
A long term study in patients treated for one year 
with a high dose (4 g/d) of 5-ASA again did not 
show any in vivo effect on TPMT activity[39]. It can 
therefore be concluded that the interaction between 
aminosalicylates and thiopurines seems not based on 
inhibition of TPMT, and other pharmacokinetic and/or 
pharmacodynamic aspects have to be investigated.
5-ASA is orally administered, is poorly absorbed 
by the gastrointestinal tract and is in part inactivated 
in the colonic mucosa by NATs[17]. These enzymes are 
widely distributed in tissues[40] and among species[41], 
and have important physiological functions; they are 
also responsible for the N-acetylation of a number 
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Figure 1  6-thioguanine nucleotides concentration and N-acetyl transferase 1 acetylator status during co-treatment of azathioprine with 5-aminosalicylic 
acid and after the interruption of the aminosalicylate. A: With 5-aminosalicylic acid; B: Without 5-aminosalicylic acid. A total of 36 samples of peripheral blood were 
collected from 12 patients to measure azathioprine metabolites; on average, 3 samples for patient were collected (range: 2-4). Among these, 19 were obtained during 
treatment with the thiopurines and 5-aminosalicylic acid (panel A) and 17 during treatment with the thiopurine alone (panel B). Samples were taken from the same 
patient with an interval of at least one month. 6-thioguanine nucleotides concentration is expressed as pmol/8 × 108 erythrocytes. 
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Thiopurines and aminosalicylates are the two most widely used drugs 
in inflammatory bowel disease (IBD) and are often used in combination. 
A significant pharmacokinetic interaction has been described for these 
medications, since this association increases the concentration of thiopurines’ 
active metabolites (TGN). 
Research frontiers
Treatment of IBD with thiopurines and aminosalicylates displays significant 
inter-patient variability in terms of efficacy and incidence of adverse events. 
Identification of determinants to predict effects of these treatments, such as 
genetic polymorphisms of enzymes involved in thiopurines and aminosalicylates 
biotransformation, is of clinical interest.
Innovations and breakthroughs
This article confirms that after interruption of aminosalicylate, concentration 
of TGNs decrease significantly. Moreover, N-acetyl-transferase 1 (NAT1) 
acetylator status, relevant for aminosalicylates biotransformation, influences 
TGN concentration during co-treatment and after the interruption of the 
aminosalicylate.
Applications 
If supported by further clinical studies, NAT1 may be incorporated in multilocus 
signatures of genotypes useful to predict the efficacy and safety of thiopurine 
and aminosalicylate co-treatment in young patients with IBD.
Terminology
TGN, the active metabolites of thiopurines, formed after biotransformation of 
mercaptopurine by enzymes of nucleotides salvage pathway. NAT1, an enzyme 
that catalyzes the acetylation of amino groups of aminosalicylates such as 
5-ASA.
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interaction between 5-aminosalicylate and thiopurines, there also seems 
to be a potentially important and previously unexplored effect of NAT 
polymorphisms.
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of xenobiotics and drugs including the aminosalicy-
lates. The activity of NAT1 and NAT2 is genetically 
determined; both genes are located on chromosome 
8p22 and a number of polymorphisms have been 
reported, allowing subjects to be classified as rapid or 
slow acetylators. The isozymes NAT1 and NAT2 have 
distinct substrate specificity and the NAT1 isozyme is 
more important (19000-fold more active) than NAT2 in 
5-ASA acetylation in vitro[42]. Interestingly, in our study, 
patients with the NAT1 slow metabolizer phenotype 
had significantly higher TGN levels in comparison with 
rapid metabolizers. The inheritance of a slow acetylator 
genotype for NAT1 could therefore lead to a reduced 
inactivation of 5-ASA, and hence to higher blood levels 
of the aminosalicylate. This could result in a reduction 
of 6MP inactivation, via a still unclear mechanism, with 
consequent increase in TGN levels. Quite unexpectedly 
however, this difference was maintained when 
measurements were performed one month after 5-ASA 
discontinuation. This may be due to the long half-life 
of TGN and the fact that a longer period is needed 
to overcome the reduction in TGN concentrations 
determined by the increased metabolism of 5-ASA. 
It is however possible that NAT1 influences TGN 
concentrations by a different mechanism, not involving 
5-ASA metabolism. 
As expected, no effect of the NAT2 polymorphism 
was observed in these patients.
In conclusion, co-administration of 5-ASA and 
thiopurines is common and probably this association will 
continue to be prescribed in light of the demonstrated 
chemopreventive activity for IBD associated colorectal 
cancer[7]. 
Since the number of patients enrolled in this study 
is limited, this has to be considered a pilot study and 
more research should be performed to evaluate if the 
difference in TGN levels observed in patients with the 
NAT1 slow acetylator phenotype are also related to an 
increased incidence of thiopurine induced side effects. 
If this were true, it might be useful to assess the NAT1 
genotype before starting therapy and, in those patients 
with a slow acetylator genotype, it might be prudent 
to start therapy with a reduced dose of AZA. Moreover, 
further studies should be performed to evaluate a 
dose dependent effect of 5-ASA or thiopurine dose 
on the association between NAT1 status and the 
pharmacokinetic interaction between 5-ASA and 
thiopurines: indeed patients with adverse NAT1 status 
may be treated with low doses of aminosalicylates, 
maintaining their chemopreventive effect. The effect 
of NAT1 acetylator status on TGN concentration in 
patients treated only with thiopurine could also be 
investigated. 
NAT1 genotyping, in addition to careful clinical 
monitoring and evaluation of thiopurine metabolites, 
might be a useful guide in those patients receiving 
azathioprine and aminosalicylates.
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